Latest Regulatory News

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Meridian Energy posted a significant net loss for FY25 due to severe droughts and gas shortages but pushed ahead with renewable investments and maintained shareholder dividends.

Yancoal Australia has appointed Sharif Burra as its permanent CEO, signaling leadership continuity amid a challenging coal market. Burra’s deep internal experience positions him to build on recent operational gains and shareholder value.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Marvel Gold Limited has restructured its Mali asset sale with Anchises Capital, securing a $250,000 equity injection while revising terms for its Tabakorole Gold Project sale.

WCM Global Growth Limited reported a robust FY2025 with a 31% portfolio return and raised its fully franked final dividend, alongside an upgraded progressive dividend policy and a shareholder-friendly DRP discount.

WCM Global Growth Limited reported a robust 53% rise in net profit for FY2025, driven by strong portfolio returns and a successful capital raise, prompting an increased final dividend and upward revision of future dividends.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Kali Metals Limited has successfully completed a placement raising approximately A$1.2 million through the issuance of new shares at A$0.14 each, reinforcing its capital position amid ongoing exploration efforts.

Arafura Rare Earths has successfully completed the first tranche of its A$80 million capital raising, issuing 369.6 million new shares and securing A$70.2 million before costs. The remaining tranche awaits shareholder approval.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.